Nomura Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.51M | Sell |
8,336
-5,963
| -42% | -$1.8M | ﹤0.01% | 1047 |
|
|
2026
Q1 | $4.73M | Sell |
14,299
-8,138
| -36% | -$2.77M | 0.01% | 664 |
|
|
2025
Q4 | $8.92M | Buy |
22,437
+20,711
| +1,200% | +$9.17M | 0.01% | 569 |
|
|
2025
Q3 | $787K | Buy |
+1,726
| New | +$703K | ﹤0.01% | 1473 |
|
|
2024
Q4 | – | Sell |
-17,849
| Closed | -$4.91M | – | 2157 |
|
|
2024
Q3 | $4.91M | Buy |
17,849
+11,423
| +178% | +$2.97M | 0.01% | 658 |
|
|
2024
Q2 | $1.56M | Buy |
+6,426
| New | +$1.01M | ﹤0.01% | 1019 |
|
|
2023
Q3 | – | Sell |
-1,572
| Closed | -$300K | – | 1361 |
|
|
2023
Q2 | $299K | Sell |
1,572
-10,779
| -87% | -$2.14M | ﹤0.01% | 1124 |
|
|
2023
Q1 | $2.47M | Buy |
+12,351
| New | +$2.6M | 0.01% | 761 |
|
|
2022
Q4 | – | Sell |
-6,113
| Closed | -$1.23M | – | 1494 |
|
|
2022
Q3 | $1.23M | Sell |
6,113
-11,330
| -65% | -$2.16M | 0.01% | 902 |
|
|
2022
Q2 | $2.58M | Buy |
+17,443
| New | +$2.47M | 0.01% | 729 |
|
|
2022
Q1 | – | Sell |
-22,403
| Closed | -$3.81M | – | 1953 |
|
|
2021
Q4 | $3.81M | Buy |
22,403
+20,674
| +1,196% | +$3.84M | 0.01% | 796 |
|
|
2021
Q3 | $332K | Sell |
1,729
-1,993
| -54% | -$374K | ﹤0.01% | 1552 |
|
|
2021
Q2 | $631K | Sell |
3,722
-2,700
| -42% | -$395K | ﹤0.01% | 1236 |
|
|
2021
Q1 | $907K | Sell |
6,422
-12,800
| -67% | -$1.93M | ﹤0.01% | 1132 |
|
|
2020
Q4 | $2.5M | Buy |
+19,222
| New | +$2.57M | ﹤0.01% | 772 |
|
|
2018
Q1 | – | Sell |
-5,488
| Closed | -$698K | – | 1415 |
|
|
2017
Q4 | $698K | Buy |
+5,488
| New | +$690K | ﹤0.01% | 1222 |
|
|
2016
Q1 | – | Sell |
-10,096
| Closed | -$951K | – | 1544 |
|
|
2015
Q4 | $951K | Buy |
10,096
+100
| +1% | +$9.27K | ﹤0.01% | 833 |
|
|
2015
Q3 | $785K | Sell |
9,996
-69,075
| -87% | -$7.67M | ﹤0.01% | 819 |
|
|
2015
Q2 | $9.05M | Buy |
+79,071
| New | +$9.45M | 0.03% | 283 |
|
|
2014
Q4 | – | Sell |
-2,690
| Closed | -$206K | – | 2265 |
|
|
2014
Q3 | $206K | Buy |
2,690
+2,687
| +89,567% | +$173K | ﹤0.01% | 2398 |
|
|
2014
Q2 | $0 | Buy |
+3
| New | +$178 | ﹤0.01% | 2718 |
|
|
2014
Q1 | – | Sell |
-3,509
| Closed | -$225K | – | 2703 |
|
|
2013
Q4 | $225K | Sell |
3,509
-28,399
| -89% | -$1.69M | ﹤0.01% | 1698 |
|
|
2013
Q3 | $2.05M | Buy |
+31,908
| New | +$1.59M | 0.01% | 820 |
|
Other funds holding ALNY
Nomura Holdings's ALNY Position: Q2 2026 in Review
Nomura Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 42% in Q2 2026, selling an estimated $1.8M and leaving 8,336 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1047.
Nomura Holdings first reported a position in ALNY in Q3 2013 and has held it in 23 quarters since. The position peaked at $9.05M in Q2 2015. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Nomura Holdings held 8,336 shares of Alnylam Pharmaceuticals worth $2.51M as of Q2 2026.
- Nomura Holdings sold 5,963 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.8M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1047 holding.
- Nomura Holdings first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 23 quarters since.
- Nomura Holdings's Alnylam Pharmaceuticals position peaked at $9.05M in Q2 2015.
- 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.